AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
ANI Pharmaceuticals, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S9DR85
72.61▼ 1.14 (-1.55%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
73.75
Day's Range
72.05 – 73.42
52-Week Range
69.58 – 97.00
Volume
308.4K
Avg Volume
380.5K
Share Statistics
Shares Outstanding
Employees
970
Exchange
XNAS
Listed
1999-09-13
Share count as of July 31, 2026

ANI Pharmaceuticals, Inc. (ANIP) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about ANI Pharmaceuticals, Inc. (ANIP)
What is ANI Pharmaceuticals, Inc.'s Market Cap?
ANI Pharmaceuticals, Inc.'s Market Cap is $1.7B, based on as-reported figures from SEC (XBRL) filings.
What is ANI Pharmaceuticals, Inc.'s Enterprise Value?
ANI Pharmaceuticals, Inc.'s Enterprise Value is $1.6B, based on as-reported figures from SEC (XBRL) filings.
What is ANI Pharmaceuticals, Inc.'s Trailing P/E?
ANI Pharmaceuticals, Inc.'s Trailing P/E is 15.4×, based on as-reported figures from SEC (XBRL) filings.
What is ANI Pharmaceuticals, Inc.'s Price / Sales?
ANI Pharmaceuticals, Inc.'s Price / Sales is 1.7×, based on as-reported figures from SEC (XBRL) filings.
What is ANI Pharmaceuticals, Inc.'s EV / Revenue?
ANI Pharmaceuticals, Inc.'s EV / Revenue is 1.6×, based on as-reported figures from SEC (XBRL) filings.
What is ANI Pharmaceuticals, Inc.'s EV / EBITDA?
ANI Pharmaceuticals, Inc.'s EV / EBITDA is 6.8×, based on as-reported figures from SEC (XBRL) filings.
What is ANI Pharmaceuticals, Inc.'s Revenue (TTM)?
ANI Pharmaceuticals, Inc.'s Revenue (TTM) is $978.4M, based on as-reported figures from SEC (XBRL) filings.
What is ANI Pharmaceuticals, Inc.'s Net Income (TTM)?
ANI Pharmaceuticals, Inc.'s Net Income (TTM) is $108.0M, based on as-reported figures from SEC (XBRL) filings.
What is ANI Pharmaceuticals, Inc.'s EBITDA?
ANI Pharmaceuticals, Inc.'s EBITDA is $236.2M, based on as-reported figures from SEC (XBRL) filings.
What is ANI Pharmaceuticals, Inc.'s Diluted EPS (TTM)?
ANI Pharmaceuticals, Inc.'s Diluted EPS (TTM) is 4.70, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ANIPAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Net Revenues
YoY growth+25.9%+20.5%+29.6%+53.6%
Operating Expenses
Cost of sales (excluding depreciation and amortization)
Research and development
Selling, general, and administrative
Depreciation and amortization
Contingent consideration fair value adjustment
Total Operating Expenses, net
% of revenue84.8%83.6%85.9%84.1%
Operating income
% of revenue15.2%16.4%14.1%15.9%
Other (expense) income, net
Unrealized gain (loss) on investment in equity securities
Interest expense, net
Other (expense) income, net
Income Before Income Tax Expense
Income tax expense
Net Income
% of revenue9.3%12.4%11.1%11.7%
Dividends on Series A Convertible Preferred Stock
Net Income Available to Common Shareholders——
Basic Income Per Share (in dollars per share)—
Diluted Income Per Share (in dollars per share)—